Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmic, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, and analgesics; and anti-oxidants, balanced energy and protein drinks, and vitamins and nutraceuticals, as well as various active pharmaceutical ingredients. It provides its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Vitcofol, Ziglim, Ziglim Plus 2, Electral, and Enerzal brand names. The company was founded in 1936 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for FDC
Revenue projections for FDC



Financial Ratios:

currentRatio 0.00000
forwardPE 15.78970
debtToEquity 0.85200
earningsGrowth -0.23700
revenueGrowth 0.00100
grossMargins 0.66139
operatingMargins 0.08069
trailingEps 13.30000
forwardEps 23.30000

FDC's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
FDC Limited's low earnings and revenue growth suggest that its profits could shrink. This points to a potential downturn in the company's financial outlook and may indicate challenges in maintaining profitability.
FDC's negative gross and operating margins suggest the company is not generating profit from either its production process or day-to-day operations. This could signal cost overruns or difficulties in maintaining revenue levels.
FDC's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting FDC to generate stronger earnings compared to the previous financial year.

Recommendation changes over time:

Recommendations trend for FDC
Recommendations trend for FDC


Analysts have maintained a buy bias for FDC, which could prompt investors to consider the stock as a viable investment. With this positive outlook, FDC is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.